Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report

Table 1 Liver tests while on raloxifene therapy and follow-up after raloxifene and fenofibrate interaction during 14 d of coadministration

Admission date	Nov 10,2003	Dec 16,2003	Dec 22,2003	Jan 2,2004	Jan 20,2004	Mar 1,2004	April 16,2004	July 2,2004	Aug 13,2004	February,2005	August,2005
Serum Bilirubin (mg/dL)
Total	-	11.07	14.91	14.33	21.84	8.31	2.81	0.72	0.78	0.65	0.83
Direct	-	9.58	14.07	13.69	19.72	7.72	1.79	0.14	-	-	-
AST (U/L)	26	153	88	36	321	97	106	84	84	45	53
ALT (U/L)	16	241	167	50	382	160	162	91	74	45	60
GGT (U/L)	21	271	239	97	1246	1387	539	1279	1255	751	666
Alkaline phosphatase (U/L)	72	174	236	240	800	420	490	1195	793	493	444
Lymphocytes (%)	26	17.7	13.8	11.5	5.9	14.3	17.7	-	27.7	33.9	32.20
VEGF (pg/mL)	-	-	-	-	144	-	-	244	-	-	-

Treatment was stopped on 14 December 2003. Total bilirubin (n < 1.8 mg/dL); AST: Aspartate aminotrasferase (n < 30 U/L); ALT: Alanine aminotransferase (n < 36 U/L); GGT: Gamma-glutamyl transpeptidase (n < 32 U/L); Alkaline phosphatase (n < 104 U/L); lymphocytes (n = 20%-40%); VEGF: Plasma vascular endothelial growth factor.